^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Cutaneous Melanoma
    Drug:paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) +
    dacarbazine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/19/2021
    Excerpt:
    Melanoma: Cutaneous...Considerations for cytotoxic agents…Other agents include dacarbazine, paclitaxel, albumin-bound paclitaxel…